LOGIN  |  REGISTER
Assertio

Checkpoint Therapeutics (NASDAQ: CKPT) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$1.70 0.02 1.19
Volume: 141,605
5-Day Change: -13.71%
YTD Change: -66.73%
Market Cap: US$35.510M

Latest News From Checkpoint Therapeutics

September 21, 2023
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City. The Company will also... Read More
September 6, 2023
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET. The Company will also attend... Read More
August 14, 2023
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results demonstrate substantial increases in complete response rates and continued favorable safety profile in advanced cutaneous squamous cell carcinoma Unique potential for cosibelimab to address a large unmet clinical need in... Read More
July 31, 2023
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc . (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common... Read More
July 27, 2023
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024 WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq:... Read More
June 28, 2023
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 WALTHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new... Read More
May 23, 2023
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock... Read More
May 15, 2023
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2023, and recent corporate highlights. “The first quarter of 2023 began a transformative year for Checkpoint, with our January submission of a Biologics License Application (“BLA”) for... Read More
March 31, 2023
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares of its common stock at a purchase price of $3.60 per share of common stock in a registered direct offering priced at-the-market... Read More
March 30, 2023
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2022, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “The past year was a momentous one for Checkpoint, and we began... Read More
March 2, 2023
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing the... Read More
February 21, 2023
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,428,572 shares of its common stock (or common stock equivalents) at a purchase price of $5.25 per share of common stock (or common stock... Read More
January 17, 2023
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3 rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST. For more... Read More
January 4, 2023
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for the approval of cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous... Read More
December 15, 2022
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 1,734,105 shares of its common stock (or pre-funded warrants in lieu thereof), Series A... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous